Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
企業コードCDXS
会社名Codexis Inc
上場日Apr 22, 2010
最高経営責任者「CEO」Dr. Stephen G. Dilly, Ph.D.
従業員数188
証券種類Ordinary Share
決算期末Apr 22
本社所在地200 Penobscot Dr
都市REDWOOD CITY
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94063
電話番号16504218100
ウェブサイトhttps://www.codexis.com/
企業コードCDXS
上場日Apr 22, 2010
最高経営責任者「CEO」Dr. Stephen G. Dilly, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし